# Beta Drugs share price today (Beta Drugs Ltd, NSE: BETA)

> Beta Drugs share price today: ₹1,769.60 at the NSE close on 4 November 2026, up 6.0% in a year. Beta Drugs (NSE: BETA) is worth ₹1,968 crore, trades at a P/E of 37.9 and has closed between ₹1,051.60 and ₹2,550.70 over the past 52 weeks. > Beta Drugs Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BETA · Pharma - API · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/beta-drugs-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹1,769.60 (+6.0% in a year)
- P/E: 37.9× (higher than 70% of the last 7.1 years)
- Revenue (Sep 2026): ₹137 Cr (+33.0% on a year ago)
- Profit (Sep 2026): ₹19.0 Cr (+58.3% on a year ago)
- Operating margin: 22.0% (+1.0 points on a year ago)
- ROCE: 19%, FY26
- Profit that came in as cash: 87%, last 3 years

The main question: promoters moved −7.8 percentage points over 8 quarters while the business went the other way. ## What is the Beta Drugs share price today? Beta Drugs Ltd's share price was ₹1,769.60 at the close on 4 November 2026. It has been rising for 18 weeks. That is 5.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,052 and ₹2,551, and at that close it sat 48% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running. Over the last 9.1 years the share price moved +1,689% while the NIFTY 500 moved +144%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Beta Drugs this quarter? Three changes stood out: indian funds and insurers (DIIs) raised their stake for 7 quarters in a row, number of shareholders up 219% in a year and highest quarterly profit in 8 quarters. 1. Indian funds and insurers (DIIs) raised their stake for 7 quarters in a row From 0.2% to 6.5% of the company by the September 2026 quarter. 2. Number of shareholders up 219% in a year 10,145 shareholders in the September 2026 quarter, against 3,184 a year earlier. 3. Highest quarterly profit in 8 quarters Profit of ₹19 crore in the September 2026 quarter is the highest of the last 8 quarters. ## What are Beta Drugs' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Beta Drugs reported revenue of ₹137 crore, up 33.0% from ₹103 crore a year earlier, and a profit of ₹19.0 crore, up 58.3% from ₹12.0 crore. ### Beta Drugs results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹137 crore | ₹103 crore | +33.0% |
| Profit | ₹19.0 crore | ₹12.0 crore | +58.3% |
| Earnings per share | ₹16.68 | ₹12.11 | +37.7% |
| Operating margin | 22.0% | 21.0% | +1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Beta Drugs' management discussed these results on a call held on 22 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Beta Drugs share price history? Beta Drugs closed at ₹1,769.60 on 4 November 2026, up 6.0% from ₹1,670.20 a year earlier (7 November 2025) and up 214.8% over five years. Its highest weekly close since October 2017 was ₹2,550.70 on 14 August 2026. ### Beta Drugs share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹1,798.40 | −1.6% |
| 1 month ago · 1 Oct 2026 | ₹2,073.30 | −14.6% |
| 6 months ago · 8 May 2026 | ₹1,322.30 | +33.8% |
| 1 year ago · 7 Nov 2025 | ₹1,670.20 | +6.0% |
| 3 years ago · 3 Nov 2023 | ₹948.19 | +86.6% |
| 5 years ago · 4 Nov 2021 | ₹562.05 | +214.8% |
| Earliest weekly close in our records · 13 Oct 2017 | ₹98.90 | +1,689.3% |
| Highest weekly close since October 2017, also the 52-week high · 14 Aug 2026 | ₹2,550.70 | −30.6% |
| Lowest weekly close since October 2017 · 25 Mar 2020 | ₹42.62 | +4,052.0% |
| 52-week low (weekly close) · 27 Feb 2026 | ₹1,051.60 | +68.3% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (477 weekly closes from 13 October 2017 to 4 November 2026.)

## What is the latest news on Beta Drugs? 4 Nov 2026: Beta Drugs closed at ₹1,769.60, down 1.6% on the week and down 14.6% on the month. 22 Oct 2026: Beta Drugs held its results call for July to September 2026. Management guided: FY27 consolidated revenue at ₹535 crore-plus. ### Earlier

- Results for July to September 2026: Revenue up 33.0% and profit up 58.3% on a year earlier. ## What dividend does Beta Drugs pay? Beta Drugs has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Beta Drugs Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Beta Drugs management say on the latest results call? On the call for July to September 2026, held on 22 October 2026, Beta Drugs' management guided: FY27 consolidated revenue at ₹535 crore-plus. > “We have been doing the CDMO business for the past 15 years. Whenever a partner has been associated with us, we have never lost that partner.”
> Nipun, on the call for July to September 2026

### What management guided

- FY27 own-brand sales of ₹150 crore. - FY27 CMO revenue of ₹180-190 crore. - Exports: ₹90-100 crore in FY27; ₹300 crore over 3-4 years at around 30% yearly growth; 50 registrations expected this year and 872 over 2-3 years. - Consolidated growth of 20-25% over 3-5 years with sustained operating margin of 23-24%. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/31755-22-Oct-2026.pdf). (From the call for July to September 2026, 22 October 2026.)

## What to watch in Beta Drugs' next results? When Beta Drugs reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Branded sales absorb the volume shifted by debottlenecking and sustain growth now that both plants operate normally. - What to check (from the call)
- Branded sales absorb the volume shifted by debottlenecking and sustain growth now that both plants operate normally. - Export registrations and tender awards convert into billed sales without relying on another large one-off opportunity order. - Nivian chain coverage and prescription activity translate into sustained organic growth and synergy-related margin improvement. - Intermediate commissioning, COFEPRIS approval and EU audit scheduling advance from pending qualifications and dossiers. ## Which stock lists is Beta Drugs on? Beta Drugs is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 1967.9715302491102](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Beta Drugs profitable? Beta Drugs Ltd earned ₹19.0 Cr of net profit in the Sep 2026 quarter, +58.3% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹41.0 Cr. Over 10 years profit has grown 45.0% a year on average. That is 13.9% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr. For the full year, FY26 profit was ₹41.0 Cr (−2.4% on the year before). Why profit moved: revenue changed +33.0% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +22.9% and revenue +14.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Beta Drugs make, and is it growing? Beta Drugs Ltd reported ₹137 Cr of revenue in the Sep 2026 quarter, +33.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 30.9% a year on average. The last full year, FY26, came in at ₹384 Cr. The last four reported quarters add to ₹444 Cr. FY26 revenue was ₹384 Cr, +6.1% on the year before. Recent pace: the last four quarters grew +14.5% on average, against 30.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +15.3%, against −13.3% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +26.2%, against −16.5% a year (accelerating). ## How much of every ₹100 of sales does Beta Drugs keep? Beta Drugs Ltd's operating margin was 22.0% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 0.0% and 23.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.4 percentage points on the year while gross margin changed +3.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Beta Drugs' profit turning into cash? Over the last 3 years, 87% of Beta Drugs Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹37.0 Cr of operating cash against ₹41.0 Cr of profit. After ₹53.0 Cr of spending on assets, free cash was −₹16.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Beta Drugs' cash go? Beta Drugs Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹384 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹102 Cr on assets over the last 3 years. Averaged over those years that is 8.9% of FY26 revenue a year. Spending on assets: ₹102 Cr over the last 3 years, against ₹40.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Beta Drugs' P/E ratio, and how does it compare with its own history? Beta Drugs Ltd's P/E is 37.9×, near the high end of its own history: higher than 70% of past readings. Its usual P/E (the middle reading) is 31.1×, over 7.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹48.26. Why the multiple is where it is: over the past year earnings per share moved −2.6% while the price moved +6.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +25.8% a year; about +20.9% a year came from earnings growth and about +4.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 50% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Beta Drugs business getting better or worse? Beta Drugs Ltd's business is turning around. Profit growth has swung from −40.0% at its low to +26.2%, improving for 3 quarters in a row, with ROCE falling at 19.0%. This is based on 12 quarters of 4 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Beta Drugs earn on its capital? Beta Drugs Ltd earned a ROCE of 19% in FY26. That is up from a low of −3% in FY15. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 10.7% net margin and 0.77× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 10.7% net margin × 0.77× asset turnover × 2.02× leverage (assets divided by equity) ≈ 16.6% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 50% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Beta Drugs have too much debt? Beta Drugs Ltd had ₹148 Cr of borrowings against ₹245 Cr of equity in FY26, so its debt is 0.60× its equity. Its operating profit is 5 times its interest bill. Over 5 years borrowings went from ₹17.0 Cr to ₹148 Cr. Over the last 3 of those years it spent ₹102 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 50% on reported income across 13 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Beta Drugs shareholding pattern? Promoters cut their stake in Beta Drugs Ltd by 7.8 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 58.9% of the company. Domestic institutions moved +6.3 points over the same period, to 6.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −7.8 points over 8 quarters, to 58.9%; Domestic institutions: +6.3 points over 8 quarters, to 6.5%; Foreign institutions: +0.2 points over 8 quarters, to 1.4%. Why the owners changed: promoters drove it (−7.8 points), with the other side taken by domestic institutions (+6.3 points). They reduced their stake. ## How far is Beta Drugs from balance-sheet trouble? For Beta Drugs Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Beta Drugs rank in its industry? 56.7 out of 100, rank 4 of 14 in Pharma - API, with 67% of the evidence available. Beta Drugs Ltd scores 56.7 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 4. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.8 + 18.4 + 8 + 10.5 = 56.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Beta Drugs compared with? Beta Drugs ranks 4 of 14 Pharma - API companies on the 4-Factor Sector Score, with 56.7 out of 100. 1. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. Beta Drugs Ltd this page BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative
12. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative
13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative
14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Beta Drugs in size? Beta Drugs is the 8th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Gujarat Themis Biosyn, Aarti Drugs and Ind-Swift Laboratories. Just below it: Jagsonpal Pharmaceuticals, Fermenta Biotech and Kopran. ### Pharma - API companies close in size

1. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) ₹4,727 crore
2. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) ₹3,972 crore
3. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) ₹3,202 crore
4. Beta Drugs Ltd ₹2,000 crore
5. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) ₹1,427 crore
6. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) ₹1,229 crore
7. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) ₹1,155 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [Brigade Hotel Ventures Ltd](https://www.sectoralpha.in/stocks/brigade-hotel-ventures-ltd) ₹2,007 crore · Hotels - Resorts
2. [Simplex Infrastructures Ltd](https://www.sectoralpha.in/stocks/simplex-infrastructures-ltd) ₹2,006 crore · Infra - Construction & Contracting
3. Beta Drugs Ltd ₹2,000 crore
4. [Elcid Investments Ltd](https://www.sectoralpha.in/stocks/elcid-investments-ltd) ₹2,000 crore · Finance - Holding Company
5. [Spandana Sphoorty Financial Ltd](https://www.sectoralpha.in/stocks/spandana-sphoorty-financial-ltd) ₹1,993 crore · Finance & Investments - Microfinance

## What else do people ask about Beta Drugs? ### What is Beta Drugs's share price today? Beta Drugs Ltd's share price is ₹1,769.60, +6.0% over the past year. The whole company is worth ₹1,968 Cr on the market. In the last 52 weeks it traded between ₹1,052 to ₹2,551; today it is 48% of the way up from the low, 5.3% below its 200-day average (as of 4 November 2026). ### What were Beta Drugs's latest quarterly results? Beta Drugs Ltd reported revenue of ₹137 Cr and net profit of ₹19.0 Cr for the Sep 2026 quarter. Revenue rose 33.0% and profit rose 58.3% compared with a year earlier. Earnings per share were ₹16.68. The operating margin was 22.0%, 1.0 percentage points higher than a year earlier (as of 4 November 2026). ### What is Beta Drugs's market cap? Beta Drugs Ltd's market capitalisation is ₹1,968 Cr at a share price of ₹1,769.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Beta Drugs performing? Beta Drugs Ltd's share price has been rising for 18 weeks. In its latest quarter, revenue rose 33.0% and profit rose 58.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 5 weeks running (as of 4 November 2026). ### Will Beta Drugs's share price go up? This page does not forecast Beta Drugs Ltd's share price. What it shows instead: the share price is ₹1,769.60, and it has been rising for 18 weeks. Its P/E of 37.9× is higher than 70% of its own last 7 years (as of 4 November 2026). ### Who owns Beta Drugs? Promoters own 58.9% of Beta Drugs Ltd, foreign institutions 1.4%, domestic institutions 6.5% and the public 33.3% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 7.8 percentage points over 8 quarters (as of 4 November 2026). ### Where is Beta Drugs in its business cycle? Beta Drugs Ltd's FY26 operating margin was 20.0%, against a 13-year range of 0.0% to 23.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 22.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Beta Drugs story? The main question: promoters moved −7.8 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Beta Drugs a stock worth studying right now? What the numbers show: Beta Drugs Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Beta Drugs share price forecast for 2026? What management itself guided: FY27 consolidated revenue at ₹535 crore-plus. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.